This snapshot, taken on
07/04/2010
, shows web content acquired for preservation by The National Archives. External links, forms and search may not work in archived websites and contact details are likely to be out of date.
 
 
The UK Government Web Archive does not use cookies but some may be left in your browser from archived websites.
Department of Health Skip to content

Please note that this website has a UK government access keys system.

Clinical information and guidance for professionals

This section contains the latest information and guidance for health professionals, in response to the swine flu pandemic.

25 March 2010: Pandemic H1N1: stand down of the antiviral distribution arrangements

This letter provides an update on the stand down of the arrangements for the distribution of antiviral medicines as part of the response to the swine flu pandemic.

27 January 2010: A (H1N1) Swine Influenza Current situation and next steps: Letter from Dr Keith Ridge, Chief Pharmaceutical Officer

This letter provides an update on the next developments in the response to the swine flu pandemic.

27 January 2010 - Pandemic H1N1 (2009) Influenza

Letter from Sir Liam Donaldson, Chief Medical Officer. With levels of influenza caused by the H1N1 (2009) pandemic virus in the community currently low, this letter provides an update on the next developments in the response to the pandemic.

27 January 2010: A (H1N1) Swine Influenza: Current situation and next steps

Letter from Ian Dalton, National Director of NHS Flu Resilience on the latest phase of our response to the H1N1 virus (swine flu).

Additional links

The 'Green Book'

Chapter 23a Pandemic influenza A(H1N1)v 2009

Central Alerting System (CAS) (opens new window)

The Central Alerting System brings together CMO’s Public Health Link (PHL) and the Safety Alert Broadcast System (SABS). It enables alerts and urgent patient safety specific guidance to be accessed at any time.

Swine flu information at the Medicines and Healthcare products Regulatory Agency (MHRA) (opens new window)

The MHRA is closely monitoring the safety of products (such as Tamiflu and Relenza) used for the treatment and prevention of swine flu during the pandemic.

Access keys